We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
When Merck reported second-quarter results last week, many pharma watchers tuned in to the fact that its blockbuster cancer fighter Keytruda finally passed market rival Opdivo in quarterly sales. Meanwhile, the company's big-selling HPV shot.....